Vir surges on up to $1.7B deal with Astellas to advance prostate cancer asset
Source: SeekingAlpha
2026-02-23 17:39:48 ET
More on Vir Biotechnology
- Vir Biotechnology: The Low-Down On The Readouts Ahead
- Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow
- Vir Biotechnology, Inc. (VIR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
- Vir Biotechnology GAAP EPS of -$0.31 beats by $0.10, revenue of $64.07M beats by $44.16M
- Vir Biotechnology Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Vir surges on up to $1.7B deal with Astellas to advance prostate cancer asset
Astellas Pharma Inc. ADR
NASDAQ: ALPMY
ALPMY Trading
-0.75% G/L:
$14.724 Last:
57,125 Volume:
$14.82 Open:
ALPMY Latest News
January 08, 2026 10:30:00 am
VYLOY(TM) (zolbetuximab) Plus Chemotherapy Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses
December 17, 2025 06:45:00 am
PADCEV(TM) Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility
December 10, 2025 06:30:00 pm
Astellas to Present New Clinical Data Across Its Gastrointestinal Cancers Portfolio at 2026 ASCO GI Cancers Symposium
ALPMY Stock Data
$29,447,472,947
1,772,218,737
N/A
5
N/A
Pharmaceuticals
Healthcare
JP
Chuo-Ku
